CANCER CARE AT THE CROSSROADS

NY, MARCH 23, 2018

A One-Day International Summit on Innovation, Clinical Benefit and Cost
8:00am – 8:15am

Opening remarks
Setting the stage for the day

MIKE MEYER
President | Meyer Consulting

WILLIAM HENRICH
MD | Professor of Medicine and President | University of Texas Health San Antonio

8:15am – 9:30am

Round table 1
Cancer Care through the Lens of Health Plans, Academic Centers, Pharma and Provider Groups - What Has Happened in the last 12 months

Moderator
STEPHEN G. EMERSON
MD, PhD | Former Director, Herbert Irving Comprehensive Cancer Center | Columbia University Medical Center

Speaker
CLIFF HUDIS
MD | Chief Executive Officer | American Society of Clinical Oncology (ASCO)

Speaker
JEFFREY Le BENER
MD | Chairman & Chief Executive Officer | Summit Medical Group / Summit Health Management

Speaker
MACE ROTHENBERG
MD | Chief Development Officer, Oncology Global Product Development | Pfizer, Inc.

Speaker
MAUREEN SULLIVAN
Chief Strategy and Innovation Officer | Blue Cross and Blue Shield Association
Program

9:30am – 10:45am

Round table 2

The Future of Cancer Treatment (Genomics, Precision Medicine, Immunotherapy, Car-T) and Genomics Driven Decision Making

Panelist

JEFFREY WEBER
MD, PhD | Deputy Director Laura and Isaac Perlmutter Cancer Center | NYU Langone Health

Panelist

JAMES GULLEY
MD, PhD | Chief, GU Malignancies Branch and Head, Immunotherapy Group, GMB; Director, Medical Oncology Services, Center for Cancer Research | NCI, NIH

Panelist

MICHEL SADELAIN
MD, PhD | Director, Center for Cell Engineering | Memorial Sloan Kettering Cancer Center

Panelist

ERIC RUBIN
MD | Senior Vice President, Global Clinical Oncology | Merck

Opening Remarks Moderator

ALEXANDER EGGERMONT
MD, PhD | Director General | Gustave Roussy (Paris), Chairman | Cancer Core Europe

Panelist

JEFFREY WEBER
MD, PhD | Deputy Director Laura and Isaac Perlmutter Cancer Center | NYU Langone Health

Panelist

JAMES GULLEY
MD, PhD | Chief, GU Malignancies Branch and Head, Immunotherapy Group, GMB; Director, Medical Oncology Services, Center for Cancer Research | NCI, NIH

Panelist

MICHEL SADELAIN
MD, PhD | Director, Center for Cell Engineering | Memorial Sloan Kettering Cancer Center

Panelist

ERIC RUBIN
MD | Senior Vice President, Global Clinical Oncology | Merck

10:45am – 11:00am

Break

11:00am – 12:15am

Round table 3

New Innovations and Technology to Improve Prevention, Diagnosis, Integrated Care, Survivorship and Palliative Care

Panelist

MICHAEL J. FISCH
MD, MPH | Medical Director, Medical Oncology Programs and Genetics | AIM Specialty Health

Panelist

GARY SCHWARTZ
MD | Deputy Director, Herbert Irving Comprehensive Cancer Center; Chief, Division of Hematology Oncology and Professor of Medicine | Columbia University

Panelist

DIANE MEIER
MD | Director, Center to Advance Palliative Care | Mount Sinai Health System, NYC

Panelist

ALAN BRYCE
MD | Vice Chair, Division of Hematology and Medical Oncology; Medical Director, Genomic Oncology Clinic | Mayo Clinic Arizona

Opening Remarks Moderator

MARY ANN CHRISTOPHER
Vice President, Clinical Operations & Transformation | Horizon Blue Cross Blue Shield of New Jersey
12:15pm – 1:15pm
Lunch served at conference center

1:15pm – 1:30pm
Afternoon Remarks

PETER S. FINE
President and CEO | Banner Health

1:30pm – 2:45pm
Round table 4
The Challenges Facing Health Plans, Providers and Governments in Financing Innovative Cancer Treatments in a Changing Health Care Policy Environment

Moderator
PETER S. FINE
President and CEO | Banner Health

Panelist
MATTHEW SHAULIS
President, North America Oncology | Pfizer, Inc

Panelist
GLEN STETTIN
MD | Chief Innovation Officer and Senior Vice President - Clinical, Research, and New Solutions | Express Scripts

Panelist
RICHARD SULLIVAN
MD, PhD | Director, Institute of Cancer Policy; Professor of Cancer & Global Health | King’s College London

Panelist
GRACE STUNTZ
Health Policy Director | Senate HELP Committee Majority Staff, US Senate
Program

3:00pm – 4:45pm
Round table 5
The Realities and Ethics of Innovative New Cancer Modalities/Types of Treatment (prevention, vaccines, immunotherapy, Car-T) and the Impact on Patients, Families, Industry and Media Perceptions

Moderator
ROBERT BAZELL
Adjunct Professor | Yale University
Former Chief Science and Health Correspondent | NBC News

Panelist
FRAN VISCO
JD | President | National Breast Cancer Coalition

Panelist
ARTHUR CAPLAN
PhD | Drs. William F and Virginia Connolly Mitty Chair; Director, Division of Medical Ethics | NYU School of Medicine

Panelist
SARAH ISELIN
Senior Vice President and Chief Strategy Officer | GuideWell / Florida Blue

Panelist
OLIVIER ELEMENTO
PhD | Director, Englander Institute for Precision Medicine | Weill Cornell Medicine

4:15pm – 4:30pm
Closing remarks
New Innovations and Technology to Improve Prevention, Diagnosis, Integrated Care, Survivorship and Palliative Care

Jacque Sokolov
MD | Chairman and CEO | S3B Solutions

Mike Meyer
President | Meyer Consulting

Copyright© 2018 Meyer Consulting
ROBERT BAZzell
Adjunct Professor | Yale University
Former Chief Science and Health Correspondent | NBC News

Robert Bazell is adjunct professor in the Department of Molecular Cellular and Developmental Biology. Before his arrival at Yale in 2013, he served for 38 years as chief science and health correspondent for NBC News. In that capacity, he earned many awards including five Emmys, the Peabody Award, and the DuPont Columbia.

He has also written extensively for many peer reviewed and general interest publications and websites. He authored a best-selling book called “Her-2: the making of a revolutionary treatment for breast cancer” which was adapted as a TV film at Yale in the CTL and the CST before it, he has set up a series of programs to train post-docs and graduate students in science to communicate more effectively with the public. He also teaches regularly in Yale College and the School of Public Health. Bazell has an undergraduate degree in biochemistry and a graduate degree in immunology from the University of California, Berkeley.

Robert Bazell
Adjunct Professor | Yale University
Former Chief Science and Health Correspondent | NBC News

Robert Bazell is adjunct professor in the Department of Molecular Cellular and Developmental Biology. Before his arrival at Yale in 2013, he served for 38 years as chief science and health correspondent for NBC News. In that capacity, he earned many awards including five Emmys, the Peabody Award, and the DuPont Columbia.

He has also written extensively for many peer reviewed and general interest publications and websites. He authored a best-selling book called “Her-2: the making of a revolutionary treatment for breast cancer” which was adapted as a TV film at Yale in the CTL and the CST before it, he has set up a series of programs to train post-docs and graduate students in science to communicate more effectively with the public. He also teaches regularly in Yale College and the School of Public Health. Bazell has an undergraduate degree in biochemistry and a graduate degree in immunology from the University of California, Berkeley.

ALAN BRYCE
MD | Vice Chair, Division of Hematology and Medical Oncology; Medical Director, Genomic Oncology Clinic | Mayo Clinic Arizona

Dr. Bryce studies cancer genetics and novel therapeutics with a focus on personalized medicine. His clinical practice centers on genitourinary malignancies (prostate, kidney, bladder, and testicular cancers) and melanoma.

He is the Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona where he utilizes whole genome sequencing of tumors to identify key driver mutations. This approach allows for precise targeting of a patient’s tumor, leading to a greater chance of remission. In addition, Dr. Bryce participates in community outreach to underserved populations and has an interest in health disparities research. He also conducts Phase I clinical trials of new cancer drugs. His areas of focus include personalized medicine, the application of genomics to prostate cancer and melanoma, and Phase I trials.

Dr. Bryce’s research centers on understanding the genetic mutations of individual cancer cells in order to allow for a precise, targeted treatment strategy. The ultimate goal is for every patient to have their tumor biopsied and sequenced, resulting in a personalized treatment plan.

ARTHUR CAPLAN
PhD | Drs. William F and Virginia Connolly Mitty Chair; Director, Division of Medical Ethics | NYU School of Medicine

Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University. Dr. Caplan is the author or editor of thirty-five books and over 725 papers in peer reviewed journals. He is a regular commentator on bioethics and health care issues for national and international media outlets.

He has served on a number of national and international committees including as the chair of the NCI Biobanking Ethics Working Group, chair of the Advisory Committee to the United Nations on Human Cloning; chair of the Advisory Committee to the Department of HHS on Blood Safety and Availability, and many others.

He is currently the ethics advisor to the DARPA (U.S. Department of Defense) on synthetic biology, a member of the University of Pennsylvania’s External Advisory Committee for its Orphan Disease Center, a member of the Ethics and Ebola Working Group of the WHO and an advisor to the NIH on organ transplantation. Dr. Caplan also serves as the chairperson of the Compassionate Use Advisory Committee (CompAC). Dr. Caplan is the recipient of many awards and honors and holds seven honorary degrees from colleges and medical schools.
MARY ANN CHRISTOPHER
Vice President, Clinical Operations & Transformation | Horizon Blue Cross Blue Shield of New Jersey

Ms. Christopher has a distinguished record of health care innovation and transformation. She serves as Vice President, Clinical Operations & Transformation at Horizon Blue Cross Blue Shield of New Jersey. She is responsible for leading clinical operations, behavioral health and medical management transformation, and overseeing the population health strategy through value-based partnerships. She is leading investigational studies in precision medicine, developing specialized oncology medical home models and facilitating care delivery transformation in palliative care.

Ms. Christopher serves as a Congressional Appointee of the National Advisory Council of Nursing Education and Practice for the U.S. Department of Health and Human Services.

Ms. Christopher has received numerous awards and recognitions, including NJBiz Top 50 Health Care Leaders, Top 50 Women in Business and the American Nurses Association Honorary Human Rights Award. Ms. Christopher is a Fellow of the American Academy of Nursing, New York Academy of Medicine, Public Health Leadership Institute of Centers for Disease Control and Prevention and the Wharton Nurse Executive Program. She has held faculty appointments at Columbia University, New York University, Rutgers University and Seton Hall University.

Ms. Christopher obtained her BSN from Fairfield University and her MSN from Seton Hall University. Awarded honorary doctoral degrees from Fairfield University and Monmouth University, she has lectured internationally and published extensively.

ALEXANDER EGGERMONT
MD, PhD | Director General | Gustave Roussy (Paris), Chairman | Cancer Core Europe

Full Professor of Oncology (2012-20) (Classe Exceptionnelle) at the Paris-Sud University in Paris, France. Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011-2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA

Specialties: His clinical specialties include immunotherapy, melanoma, sarcoma and regional therapy techniques as well as general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models and tumor pathophysiology.

Scientific Output: He is an author or co-author of > 700 peer-reviewed publications, book chapters and monographs. More than 35 PhD theses have originated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-Index: 69; >23000 citations

International functions
– European Academy of Cancer Sciences: President, 2010-2016
– Cancer Core Europe President – 2014-2017
– ECCO: Past President
– EORTC: Past President
– ASCO: Past Board Member (Surgery Chair) and JCO Editorial Board
– AACR: Past Deputy Editor of Clinical Cancer Research
– Deutsche Krebshilfe: Chair International Jury for Comprehensive Cancer Centers Program
– FNCLCC: Vice President French Federation of Cancer Centers
– European Journal of Cancer: Editor-in-Chief since 2011

Societal Awards:
– Presidential Medical, Kazakhstan (2014)
– Legion d’Honneur, France (2015)

OLIVIER ELEMENTO
PhD | Director, Englander Institute for Precision Medicine | Weill Cornell Medicine

Olivier Elemento, Ph.D. is the Director of the Caryl and Israel Englander Institute for Precision Medicine. He is also Associate Director of the Institute for Computational Medicine. Director of the Laboratory of Cancer Systems Biology/Co-Leader of the Genomics, Epigenetics, and Systems Biology Program in the Meyer Cancer Center at Weill Cornell Medicine and Associate Professor in the Department of Physiology and Biophysics. His group combines Big Data with experimentation and genomic profiling to accelerate the discovery of cancer cures. He and his group have published over 170 scientific papers in the area of genomics, epigenomics, computational biology and drug discovery.

Dr. Elemento and his group have developed new assays and analytical pipelines for cancer genome and epigenome analysis, clinical sequencing and precision medicine. He led the development the first New York State approved whole exome sequencing test for oncology. He and his group developed new methods for assessing tumor-driving pathways, the immune landscape of tumors and predicting immunotherapy responders. In addition, he developed methodologies to repurpose existing drugs to target specific pathways, predict drug toxicity and identify synergistic drug combinations. He has also developed augmented reality approaches for visualizing complex biomedical information. His research has been highlighted in several broad audience media outlets, including Popular Science, CBS, Gizmodo, Huffington Post.

Dr. Elemento is the recipient of several awards including the NSF CAREER Award, the Hirschl Trust Career Scientist Award, the Walter B Wriston Award, the Deadalus Award, the Siegel Family Award for Outstanding Research.
Peter S. Fine was appointed President and CEO of Phoenix, Arizona based Banner Health in November 2000. Prior to his appointment, he was EVP and COO of Milwaukee, Wisconsin based Aurora Health Care. Before joining Aurora, Mr. Fine served in several hospital leadership positions, including President and CEO of Grant Hospital and SVP of Operations at Northwestern Memorial Hospital, both in Chicago, and Assistant Administrator of Porter Memorial Hospital in Valparaiso, Indiana.

Mr. Fine received his bachelor's degree from Ohio University and his master's degree in healthcare administration from George Washington University. He is a fellow in the American College of Healthcare Executives and previously served as a member of their Board of Governors. He is also a member of the American Hospital Association, Health Management Academy, Greater Phoenix Leadership, Governor's Transformation Advisory Committee, and serves on the board of directors for Premier, Inc., and the Banner Health Board of Directors; previously served on the boards of Accuray, Translational Genomics Research Institute, the Heard Museum and had a prior term of service on the Board of Directors for Premier Inc.

A number of prestigious organizations have honored Mr. Fine including, Modern Healthcare with the 100 Most Influential People in Healthcare Award (2011, 2014, 2015), Modern Healthcare and Healthcare Information and Management Systems Society with the 2010 CEO IT Achievement Award, Phoenix Business Journal's Most Admired CEO Award 2010, and many others.

Stephen G. Emerson
MD, PhD | Former Director, Herbert Irving Comprehensive Cancer Center | Columbia University Medical Center

Dr. Emerson graduated Haverford College and went on to Yale University, where he received a Master of Science degree in molecular biophysics; a Ph.D. in cell biology and immunology, and his medical degree. He served on the faculties of the University of Michigan and Harvard University before joining the University of Pennsylvania in 1994. Dr. Emerson is a renowned investigator in bone marrow stem cell biology who has been recognized with several awards, including the Stohlman Award of the Leukemia and Lymphoma Society, the Medical Scientist Traineer Prize of Yale University, the Wilbur Cross Medal from Yale University, its highest honor for its Ph.D. graduates, and the Bai-Yu Lan Prize of the City of Shanghai, the Rolex Career Achievement Award, and most recently elected a Knight of the French Legion of Honor.

He has been actively involved with grant review and scientific program review at the National Institutes of Health and National Science Foundation. He sat on the leadership councils of the American Society of Hematology and the American Society for Blood and Marrow Transplantation, serving as Scientific Program Director for the annual meetings of each. He was a member of the Journal of Experimental Medicine and Blood Editorial Board and served as Senior Editor of the Journal of Clinical Investigation. In the laboratory, Dr. Emerson performs research in bone marrow stem cell biology, particularly as applied to bone marrow stem cell transplantation. Researchers in his laboratory have made discoveries that have led to new medical therapies used worldwide.

Michael J. Fisch
MD, MPH | Medical Director, Medical Oncology Programs and Genetics | AIM Specialty Health

Dr. Fisch is an experienced internist who is subspecialty board certified in medical oncology and palliative care in addition to internal medicine. He has been elected as a fellow of ASCO, the AAHPI, and the ACP. Before coming to AIM Specialty Health 2 years ago, he was Professor and Chair of the Department of General Oncology at MD Anderson Cancer Center in Houston, Texas. He maintains clinical practice with MD Anderson, seeing oncology outpatients in Houston on Fridays. Dr. Fisch has received teaching awards and published 80 peer-reviewed papers, along with 17 book chapters. He has co-edited 4 multi-authored books related to palliative care and oncology. He served as the Chair for the inaugural ASCO Palliative Care in Oncology Symposium in October of 2014. In addition, he served as Co-Chair of the National Cancer Institute’s Symptom Management and Quality of Life Committee from 2007-2014, and received the NCI Director’s Award for his service in this role. He is currently Co-Chair of the SWOG Symptom Control and Quality of Life committee.
WILLIAM HENRICH
MD | Professor of Medicine and President | University of Texas Health San Antonio

William L. Henrich, MD, MACP, a specialist in kidney diseases, has served as the president of The University of Texas Health Science Center at San Antonio (now called UT Health San Antonio) since 2009. He received his undergraduate degree from Columbia University and his medical degree from Baylor College of Medicine, and later completed a residency in Internal Medicine at The University of Oregon Medical School and a fellowship in Nephrology at The University of Colorado School of Medicine.

Dr. Henrich served as Professor of Medicine at The University of Texas Southwestern School of Medicine, as Professor and Chair of Medicine at the Medical College of Ohio, and as the Theodore Woodward Professor and Chairman of the Department of Medicine at The University of Maryland School of Medicine in Baltimore. He became the Dean of the School of Medicine and Vice President for Medical Affairs at The University of Texas Health Science Center at San Antonio in 2006.

He is the author of over 300 articles and chapters, and the founding editor of the popular dialysis textbook “Principles and Practice of Dialysis” (now renamed “Henrich’s Principles and Practice of Dialysis”). He has research interests in hemodynamic stability during dialysis and the intrarenal renin-angiotensin system.

JAMES GULLEY
MD, PhD | Chief, GU Malignancies Branch and Head, Immunotherapy Group, GMB; Director, Medical Oncology Services, Center for Cancer Research | NCI, NIH

Dr. James Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. He graduated from Loma Linda University in California with a Ph.D. in microbiology in 1994 and an M.D. in 1995. As part of this eight-year M.D./Ph.D. Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.

Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or Associate Investigator on more than 100 trials. These innovative investigator initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, he has played a central role in the clinical development of a prostate cancer vaccine, created in the NCI, and serves as the principal investigator on an international Phase III randomized clinical trial of this vaccine. He is also the coordinating principal investigator of an international trial of an anti-PDL1 antibody and several other international immunotherapy studies. Dr. Gulley is most excited by efforts to expand the clinical utility of immune checkpoint modulators into non-T-cell inflamed tumors through combination with therapeutic vaccines and other immunotherapies.

Dr. Gulley has authored more than 200 scientific papers and book chapters, edited 5 books and has made numerous invited presentations at national and international meetings.

CLIFF HUDIS
MD | Chief Executive Officer | American Society of Clinical Oncology (ASCO)

Dr. Hudis is the CEO of the American Society of Clinical Oncology, the largest professional society in the world dedicated to education, research, and quality of care for patients with cancer. Among many other current initiatives, ASCO is developing CancerLinQ, a not-for-profit subsidiary that will organize real world big data to provide into usable knowledge, personalized for individual patients.

Before his move to ASCO, Dr. Hudis served for nearly two decades as the Chief of the Breast Medicine Service and Attending Physician at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City where he was also a Professor of Medicine at the Weill Medical College of Cornell University. He was co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group), Chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation, and a former Associate Editor of the Journal of Clinical Oncology. He also served as MSKCC’s Vice President for Government Relations and Chief Advocacy Officer and he continues to maintain a limited clinical practice at that institution.
Speakers

**DIANE MEIER**
MD | Director, Center to Advance Palliative Care | Mount Sinai Health System, NYC

Dr. Diane E. Meier is Director of the Center to Advance Palliative Care (CAPC), a national organization devoted to increasing the number and quality of palliative care programs in the United States. Under her leadership the number of palliative care programs in U.S. hospitals has more than tripled in the last 10 years. She is Professor of Geriatrics and Palliative Medicine, Catherine Gaisman Professor of Medical Ethics; and was the founder and Director of the Hertzberg Palliative Care Institute from 1997-2011, all at Mount Sinai School of Medicine in New York City, where she has been on the faculty since 1983.

Dr. Meier was named one of 20 People Who Make Healthcare Better in the U.S. by HealthLeaders Media 2010. She has received numerous honors, including a MacArthur Foundation Fellowship in September of 2008 and the Gustav O. Lienhard Award from the National Academy of Sciences in 2017.

Dr. Meier has over 200 peer reviewed publications in the medical literature. She received her BA from Oberlin College and MD from Northwestern, and completed her residency and fellowship training at OHSU in Portland.

**SARAH ISELIN**
Senior Vice President and Chief Strategy Officer | GuideWell/Florida Blue

Sarah Iselin is GuideWell's Senior Vice President and Chief Strategy Officer. In this role, she serves as a member of the Enterprise Executive Management Team and leads strategy, brand and integrated market intelligence for the company. Sarah was most recently President of Optum's federal government business. She joined Optum after serving as the senior vice president of strategy, policy and community partnerships and chief strategy officer for Blue Cross Blue Shield of Massachusetts. From 2010-2012, Sarah was the president of the Blue Cross Blue Shield of Massachusetts Foundation, one of the largest private health philanthropies in Massachusetts. Sarah came to the Foundation after serving as the Commissioner of the Massachusetts Division of Health Care Finance and Policy.

Sarah earned a master's degree in health policy and management from the Harvard School of Public Health and her undergraduate degree from the School of the Art Institute of Chicago.

**JEFFREY LE BEMBERG**
MD | Chairman & Chief Executive Officer | Summit Medical Group / Summit Health Management

Jeffrey Le Benger, MD, is Chairman & CEO of Summit Medical Group (SMG) and Summit Health Management (SHM) in Berkeley Heights, New Jersey. Founded in 1929, SMG is the largest and oldest physician-owned multispecialty medical practice in the New York/New Jersey metropolitan area and among the largest in the nation. Under Dr. Le Benger’s leadership in 2014, SMG also created SHM, a management services company with a focus on population health management.

In 2014, Dr. Le Benger spearheaded a new relationship between SMG and MD Anderson Cancer Center to develop a new outpatient cancer center. The relationship is the first of its kind between the world-class cancer provider and a physician-owned multispecialty medical group. Dr. Le Benger earned his medical degree from New York Medical College. He did his residency training at Mount Sinai Medical Center and he is board certified in otolaryngology, head and neck surgery, and facial plastic and reconstructive surgery.
ERIC RUBIN  
MD | Senior Vice President, Global Clinical Oncology | Merck

Dr. Rubin has focused on cancer drug development for over 25 years. His initial research efforts focused on mechanisms of resistance to DNA topoisomerase-targeting drugs and his laboratory cloned a novel topoisomerase I- and p53-interacting tumor suppressor gene, TOPORS. In 2008 Dr. Rubin was recruited to Merck as Vice-President, Oncology Clinical Research. He led the initial development of the anti-PD-1 antibody pembrolizumab, which was the first anti-PD-1 therapy approved in the U.S., and in the identification of the significant activity of this antibody across several additional cancer types. In his current role he oversees oncology early development and translational research activities at Merck.

Dr. Rubin has authored over 100 original, peer-reviewed publications and book chapters related to oncology translational research, clinical trials and drug development. Dr. Rubin obtained his medical degree from the University of South Florida, completed residency at Yale-New Haven Hospital, and oncology fellowship at the Dana-Farber Cancer Institute.

MACE ROTHENBERG  
MD | Chief Development Officer, Oncology Global Product Development | Pfizer, Inc.

At Pfizer, Dr. Rothenberg’s key responsibilities include membership on the leadership teams for Global Product Development and Pfizer Oncology and membership on Pfizer’s Senior Leadership Council. Outside of his responsibilities at Pfizer, Dr. Rothenberg co-chairs the Life Sciences Consortium of the CEO Roundtable on Cancer, a member of the National Cancer Policy Forum of the National Academy of Medicine and serves on the NYU School of Medicine Alumni Board of Governors.

Dr. Rothenberg came to Pfizer in 2008 after 25 years in academia where he focused on early-stage drug development, clinical trial design, and the coordinated laboratory-clinical evaluation of new therapies for gastrointestinal cancers. While in academia, Dr. Rothenberg was involved with pivotal clinical trials that led to FDA approval of irinotecan (CPT-11, Camptosar®) in 1996, oxaliplatin (Eloxatin®) in 2002, and Gemzar® in 1996. At Pfizer, Dr. Rothenberg led the successful development of 4 new cancer drugs that received FDA approval within a 5 year span: crizotinib (Xalkoriin 2011, axitinib (Inlyta®) in 2012, bosutinib (Bosulif®) in 2012, and palbociclib (Ibrance®) in 2015.

Dr. Rothenberg is the recipient of the American Cancer Society’s Lane W. Adams Quality of Life Award and the American Society of Clinical Oncology’s Statesman Award. He is a Fellow of the American College of Physicians and ASCO. Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982.

MIKE MEYER  
President | Meyer Consulting

Mike Meyer has spent his career serving healthcare organizations in their strategic and human capital initiatives. Over these years he has built multiple businesses. Meyer is known for his work with health care leaders; his extensive network and in-depth knowledge about healthcare, the intersection among science and practice, how it is funded and delivered, and the policy changes that drive the industry. His recruits, strategic partnerships and other consulting work have positively changed organizations, driven top- and bottom-line growth, and created new healthcare organizations.

Meyer founded Meyer Consulting in 2007 to offer healthcare organizations a consulting firm that has a unique business model encompassing strategic and marketing consulting, human capital consulting and executive search. Before forming Meyer Consulting, he founded and built the insurance practice and served as a board member at Witt/ Kieffer, the largest healthcare executive search firm in the US. He was also the vice president in charge of the New York
**Speakers**

**MICHEL SADELAIN**  
**MD, PhD | Director, Center for Cell Engineering | Memorial Sloan Kettering Cancer Center**

Dr. Sadelain has made major contributions to the generation and optimization of CAR T cells to treat cancer, as well as the development of stem cell therapies for blood disorders. Dr. Sadelain’s work has focused on developing novel strategies to extend survival of CAR T cells in the body and enable T cells with increased potency to overcome the resistance imposed by tumor and other cells in the tumor microenvironment.

Dr. Sadelain is founding director of the Center for Cell Engineering and head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan Kettering Cancer Center (MSKCC), where he holds the Stephen and Barbara Friedman Chair. Dr. Sadelain is also a member of the departments of medicine and pediatrics at Memorial Hospital and the molecular pharmacology and chemistry program of the Sloan Kettering Institute.

Dr. Sadelain received his M.D. from the University of Paris, France, in 1984 and his Ph.D. from the University of Alberta, Canada, in 1989. After completing a clinical residency at the Centre Hospitalier Universitaire Saint-Antoine in Paris, Dr. Sadelain carried out a postdoctoral fellowship with Richard Mulligan, Ph.D., at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, before joining MSKCC in 1994 as an assistant member. He has authored more than 150 scientific papers and book chapters.

**GARY SCHWARTZ**  
**MD | Deputy Director, Herbert Irving Comprehensive Cancer Center; Chief, Division of Hematology Oncology and Professor of Medicine | Columbia University**

Dr. Schwartz is a recognized leader in the field of translational research and has been able to bridge the clinical and basic science elements of drug development. Previously, he was an Attending Physician and Member at Memorial Sloan-Kettering Cancer Center and Chief of the Melanoma Sarcoma Oncology Service. His clinical focus is in melanoma and sarcoma.

He is the PI of a series of phase I and II trials that are based on his laboratory studies. His work has extensively been supported by his own peer-reviewed grants. This has included an R01 to develop cyclin dependent kinase inhibitors with chemotherapy, an R01 and a SPORE grant to evaluate combinations of receptor tyrosine kinase inhibitors of IGF-1R and PDGFR with inhibitors of mTOR in sarcomas, a RAID and an R21 grant to develop the sphingosine kinase inhibitor safingol with cisplatin, a DOD-R01 to develop the botanical herb huanglian, and an FDA-R01 to develop imatinib for the treatment of patients with c-kit mutant melanomas.

He is PI of the Columbia University Minority/Underserved Site NCI Community Oncology Research Program. He has received multiple awards for his contributions to teaching and mentoring. Dr. Schwartz has authored or co-authored over 200 peer-reviewed publications and has served on numerous committees for ASCO, AACR, the NCI, and others.

**MATTHEW SHAULIS**  
**President, North America Oncology | Pfizer, Inc**

Matt Shaulis currently serves as the President of Pfizer Oncology North America. Matt has more than 18 years of experience in the pharmaceutical industry across several functions including, in-line and global strategic marketing, sales management, strategic customers group, licensing, and acquisitions, finance, and compound and indication launches across multiple disease states.

Most recently, Matt served as the VP U.S. Oncology Commercial with responsibility for RCC, Lung, and Immuno-Oncology Marketing as well as Hematology Oncology Sales & Marketing. He joined Pfizer from Teva Pharmaceuticals, where he was Vice President, Global CNS, Multiple Sclerosis. Prior to that, Matt was the Head of Oncology Sales & Strategic Customer Group at Teva and from 2007—2010, Matt was the Head of Oncology Marketing at Cephalon before the company was acquired by Teva.

Before joining Cephalon in 2007, he served in various line management and global roles within Oncology and other therapeutic areas at Johnson & Johnson and Schering-Plough. Matt earned his bachelor degree from Penn State University and his MBA from Duke University, The Fuqua School of Business.
**JACQUE SOKOLOV**

MD | Chairman and CEO | SSB Solutions

Jacque J. Sokolov, M.D. is chairman and chief executive officer of SSB Solutions, Inc., a US based, diversified healthcare management, development and financial services company currently operating in over 20 states. Following his formal training as an academic cardiologist, Dr. Sokolov has had the opportunity to serve as board director, corporate officer and advisor, in multiple healthcare sectors.

He started his career as Vice President for Healthcare and Chief Medical Officer for Southern California Edison Corporation (NYSE:EIX). Dr. Sokolov currently serves or has served in multiple board capacities for Public/Private Companies including Hospira (NYSE:HSP), MediCath (NASDAQ:MDTH), PhyAmerica (NYSE:ERDR) GlobalMed, SMG Holdings; and Non Profit Organizations including Phoenix Children’s Hospital, The National Health Foundation, the American College of Medical Quality, and White House Health Project.

Dr. Sokolov received his BA and MD Degree from the University of Southern California. He completed his internal medicine residency at the Mayo Graduate School of Medicine and his fellowship in cardiovascular diseases from the University of Texas-Southwestern Medical School. He previously held and currently holds academic appointments and advisory board responsibilities in the Schools of Medicine, Business and Public Health at Harvard, the Massachusetts Institute of Technology, the University of Pennsylvania, the University of California, Los Angeles, and the University of Southern California.

---

**GLEN STETTIN**

MD | Chief Innovation Officer and Senior Vice President - Clinical, Research, and New Solutions | Express Scripts

Dr. Stettin leads Express Scripts’ development of solutions that help employers and other health-plan sponsors to reduce costs while improving members’ health outcomes. His responsibilities include research, analytics, reporting, formulary and trend management, as well as clinical product development including Consumerology® and specialized care through Express Scripts’ Therapeutic Resource Centers®.

A board-certified physician and business leader, Glen has a passion for innovation and evidence-based, data-driven healthcare. He previously served as chief medical officer at Medco; and has practiced internal medicine and emergency medicine in New Jersey and California. He completed his residency in internal medicine and fellowship training at the University of California, San Francisco, where he also served as Medical Chief Resident at Moffitt Hospital, and as a Robert Wood Johnson Clinical Scholar.

---

**GRACE STUNTZ**

Health Policy Director | Senate HELP Committee Majority Staff, US Senate

Grace Stuntz is Health Policy Director for Lamar Alexander (R-TN), Chairman of the Health, Education, Labor, and Pensions Committee (HELP). Grace has worked on the HELP Committee since 2011, previously working for Ranking Member Enzi, focusing on FDA policy.

She’s worked on major legislative efforts including the FDA Safety and Innovation Act, Drug Quality and Security Act, and 21st Century Cures Act.

She received her B.S. in Biomedical Engineering and Master of Public Policy (MPP) from the University of Virginia.
The page contains information about three speakers: Maureen Sullivan, Richard Sullivan, and Fran Visco. Each speaker's profile includes their professional background, achievements, and contributions to their respective fields.
JEFFREY WEBER
MD, PhD | Deputy Director Laura and Isaac Perlmutter Cancer Center | NYU Langone Health

Dr. Weber is the Deputy Director of the Laura and Isaac Perlmutter Cancer Center, Head of Experimental Therapeutics as well as Professor of Medicine at the NYU-Langone Medical Center in New York City.

His research interests lie in the monitoring and characterization of T cell responses to immunotherapeutic treatments in cancer patients, and in the establishment of in vitro models to facilitate the understanding of how immune modulating antibodies amplify T cell responses in patients. He is also interested in the mechanisms by which achieving autoimmunity induces regression of cancer.

His clinical interests are in the immunotherapy of melanoma and other malignancies, with a focus on adoptive immunotherapy, epigenetic therapy and the use of immune modulating antibodies.
Meyer Consulting is an international health care consulting and recruiting firm that brings leading experts together in collaborative settings to build better health care solutions.